Oncogenic ALK Regulates EMT in Non-small Cell Lung Carcinoma Through Repression of the Epithelial Splicing Regulatory Protein 1

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Apr 28

PMID 27119231

Citations 23

Authors

Claudia Voena

Lydia M Varesio

Liye Zhang

Matteo Menotti

Teresa Poggio

Elena Panizza

Qi Wang

Valerio G Minero

Sharmila Fagoonee

Mara Compagno

Fiorella Altruda

Stefano Monti

Roberto Chiarle

Affiliations

Soon will be listed here.

Abstract

A subset of Non-Small Cell Lung Carcinoma (NSCLC) carries chromosomal rearrangements involving the Anaplastic Lymphoma Kinase (ALK) gene. ALK-rearranged NSCLC are typically adenocarcinoma characterized by a solid signet-ring cell pattern that is frequently associated with a metastatic phenotype. Recent reports linked the presence of ALK rearrangement to an epithelial-mesenchymal transition (EMT) phenotype in NSCLC, but the extent and the mechanisms of an ALK-mediated EMT in ALK-rearranged NSCLC are largely unknown. We found that the ALK-rearranged H2228 and DFCI032, but not the H3122, cell lines displayed a mesenchymal phenotype. In these cell lines, oncogenic ALK activity dictated an EMT phenotype by directly suppressing E-cadherin and up-regulating vimentin expression, as well as expression of other genes involved in EMT. We found that the epithelial splicing regulatory protein 1 (ESRP1), a key regulator of the splicing switch during EMT, was repressed by EML4-ALK activity. The treatment of NSCLC cells with ALK tyrosine kinase inhibitors (TKIs) led to up-regulation of ESRP1 and E-cadherin, thus reverting the phenotype from mesenchymal to epithelial (MET). Consistently, ESRP1 knock-down impaired E-cadherin up-regulation upon ALK inhibition, whereas enforced expression of ESRP1 was sufficient to increase E-cadherin expression. These findings demonstrate an ALK oncogenic activity in the regulation of an EMT phenotype in a subset of NSCLC with potential implications for the biology of ALK-rearranged NSCLC in terms of metastatic propensity and resistance to therapy.

Citing Articles

ALK in cancer: from function to therapeutic targeting.

Voena C, Ambrogio C, Iannelli F, Chiarle R Nat Rev Cancer. 2025; .

PMID: 40055571 DOI: 10.1038/s41568-025-00797-9.

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E J Hematol Oncol. 2025; 18(1):6.

PMID: 39806516 PMC: 11733683. DOI: 10.1186/s13045-024-01634-6.

Senescence cell signature associated with poor prognosis, epithelial-mesenchymal transition, solid histology, and spread through air spaces in lung adenocarcinoma.

Koh Y, Han J, Haam S, Lee H Geroscience. 2024; .

PMID: 39546155 DOI: 10.1007/s11357-024-01442-3.

MicroRNAs as the critical regulators of epithelial mesenchymal transition in pancreatic tumor cells.

Tolue Ghasaban F, Ghanei M, Mahmoudian R, Taghehchian N, Abbaszadegan M, Moghbeli M Heliyon. 2024; 10(9):e30599.

PMID: 38726188 PMC: 11079401. DOI: 10.1016/j.heliyon.2024.e30599.

Systematic analysis of the effects of splicing on the diversity of post-translational modifications in protein isoforms using PTM-POSE.

Crowl S, Coleman M, Chaphiv A, Jordan B, Naegle K bioRxiv. 2024; .

PMID: 38260432 PMC: 10802621. DOI: 10.1101/2024.01.10.575062.

References

De Craene B, Berx G . Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013; 13(2):97-110. DOI: 10.1038/nrc3447. View

Fischer K, Durrans A, Lee S, Sheng J, Li F, Wong S . Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015; 527(7579):472-6. PMC: 4662610. DOI: 10.1038/nature15748. View

Peinado H, Olmeda D, Cano A . Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007; 7(6):415-28. DOI: 10.1038/nrc2131. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Guo F, Liu X, Qing Q, Sang Y, Feng C, Li X . EML4-ALK induces epithelial-mesenchymal transition consistent with cancer stem cell properties in H1299 non-small cell lung cancer cells. Biochem Biophys Res Commun. 2015; 459(3):398-404. DOI: 10.1016/j.bbrc.2015.02.114. View

Sang J, Acquaviva J, Friedland J, Smith D, Sequeira M, Zhang C . Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov. 2013; 3(4):430-43. PMC: 4086149. DOI: 10.1158/2159-8290.CD-12-0440. View

Martinengo C, Poggio T, Menotti M, Scalzo M, Mastini C, Ambrogio C . ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis. Cancer Res. 2014; 74(21):6094-106. DOI: 10.1158/0008-5472.CAN-14-0268. View

Kogita A, Togashi Y, Hayashi H, Sogabe S, Terashima M, De Velasco M . Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition. Int J Oncol. 2014; 45(4):1430-6. PMC: 4151805. DOI: 10.3892/ijo.2014.2574. View

Voena C, Peola S, Chiarle R . The anaplastic lymphoma kinase as an oncogene in solid tumors. Front Biosci (Schol Ed). 2015; 7(2):269-82. DOI: 10.2741/S440. View

10.

Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H . Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131(6):1190-203. DOI: 10.1016/j.cell.2007.11.025. View

11.

Prudkin L, Liu D, Ozburn N, Sun M, Behrens C, Tang X . Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol. 2009; 22(5):668-78. PMC: 2675657. DOI: 10.1038/modpathol.2009.19. View

12.

Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M . EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008; 3(1):13-7. DOI: 10.1097/JTO.0b013e31815e8b60. View

13.

Schliekelman M, Taguchi A, Zhu J, Dai X, Rodriguez J, Celiktas M . Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival. Cancer Res. 2015; 75(9):1789-800. PMC: 4846295. DOI: 10.1158/0008-5472.CAN-14-2535. View

14.

Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N . A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell. 2009; 15(6):489-500. PMC: 2743093. DOI: 10.1016/j.ccr.2009.03.022. View

15.

Valastyan S, Weinberg R . Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011; 147(2):275-92. PMC: 3261217. DOI: 10.1016/j.cell.2011.09.024. View

16.

Thiery J, Acloque H, Huang R, Nieto M . Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139(5):871-90. DOI: 10.1016/j.cell.2009.11.007. View

17.

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

18.

Lee J, Dedhar S, Kalluri R, Thompson E . The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006; 172(7):973-81. PMC: 2063755. DOI: 10.1083/jcb.200601018. View

19.

Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W . A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011; 71(18):6051-60. PMC: 3278914. DOI: 10.1158/0008-5472.CAN-11-1340. View

20.

Huang S, Holzel M, Knijnenburg T, Schlicker A, Roepman P, McDermott U . MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell. 2012; 151(5):937-50. PMC: 3672971. DOI: 10.1016/j.cell.2012.10.035. View